No Data
BrightGene Bio-Medical Technology's (SHSE:688166) Earnings Have Declined Over Three Years, Contributing to Shareholders 13% Loss
Third Quarter Report 2024
brightgene bio-medical technology co.,ltd. (688166.SH): The net income in the first three quarters was 0.177 billion yuan, a decrease of 7.50% year-on-year.
On October 29, Brightgene Bio-medical Technology Co.,Ltd. (688166.SH) announced its third quarter report for 2024, with the company's revenue for the first three quarters of the year at 0.977 billion yuan, a year-on-year increase of 6.77%; net income attributable to shareholders of the listed company at 0.177 billion yuan, a year-on-year decrease of 7.50%; basic earnings per share of 0.42 yuan.
The Recent 4.6% Gain Must Have Brightened CEO Jiandong Yuan's Week, BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) Most Bullish Insider
BrightGene Bio-Medical Technology Completes Phase II Clinical Trial for Weight Loss Drug
brightgene bio-medical technology co.,ltd. (688166.SH): BGM0504 injection achieved the expected goal in phase II clinical trial for overweight or obese non-diabetic patients.
Brightgene Bio-medical Technology Co., Ltd. (688166.SH) announced on October 13 that its wholly-owned subsidiary, Brightgene New Creation Biomedical Technology (Wuxi) Co., Ltd. (referred to as "Brightgene New Creation"), has achieved the expected target in the phase II clinical trial of BGM0504 injection developed independently for the treatment of non-diabetic overweight or obese individuals. The preliminary results of the phase II clinical trial for BGM0504 injection in the treatment of overweight or obese individuals show that the subjects in the 5mg, 10mg, and 15mg dose groups receiving once-weekly dosing for 26 to 30 weeks demonstrated good overall tolerability and safety.
BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 31% Share Price Plunge Could Signal Some RiskNo Data
No Data
